Design, synthesis and evaluation of a novel cyclohexanamine class of neuropeptide Y Y1 receptor antagonists
摘要:
A novel series of cyclohexanamine derivatives was designed and synthesized as potent and selective human neuropeptide Y Y1 receptor antagonists. Modification of high-throughput screening hit compound 1 resulted in the identification of compound 3i, which displays potent Y1 activity and good selectivity towards hERG K(+) channel and serotonin transporter. (C) 2009 Elsevier Ltd. All rights reserved.
[EN] CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE CYCLOPROPYLE UTILISES COMME ANTAGONISTES DU RECEPTEUR DE NK3
申请人:LUNDBECK & CO AS H
公开号:WO2005016884A1
公开(公告)日:2005-02-24
The present invention relates to cyclopropyl derivatives of formula (I) and salt thereof. These compounds are NK3 receptor antagonists and may therefore be useful for treatment of diseases where the NK3 receptor is implicated, e.g. psychotic disorders.
Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them
申请人:——
公开号:US20040220223A1
公开(公告)日:2004-11-04
Compounds of formula (I), a method for obtaining them and pharmaceutical compositions containing them are described. The compounds are useful as human NK
3
receptor antagonists.
Cyclopropyl derivatives as nk3 receptor antagonists
申请人:Kehler Jan
公开号:US20060281746A1
公开(公告)日:2006-12-14
The present invention relates to cyclopropyl derivatives of formula (I) and salt thereof. These compounds are NK3 receptor antagonists and may therefore be useful for treatment of diseases where the NK3 receptor is implicated, e.g. psychotic disorders.
Identification of a new series of non-peptidic NK3 receptor antagonists
作者:Karsten Juhl、Tore Hansen、Jan Kehler、Nikolay A. Khanzhin、Morten B. Nørgaard、Thomas Ruhland、Dorrit B. Larsen、Klaus G. Jensen、Björn Steiniger-Brach、Søren M. Nielsen、Klaus B. Simonsen
DOI:10.1016/j.bmcl.2010.12.135
日期:2011.3
The identification and structure-activity relationships of 2-aminomethyl-1-aryl cyclopropane carboxamides as novel NK3 receptor antagonists are reported. The compound series was optimized to give analogues with low nanomolar binding to the NK3 receptor and brain exposure, leading to activity in vivo in the senktide-induced hypoactivity model in gerbils. (C) 2011 Elsevier Ltd. All rights reserved.
5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST